More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Listener Feedback

Million Hearts

CMS 'Million Hearts' CVD Risk Reduction Model Works

https://www.medscape.com/viewarticle/997551

-  RCT JAMA -    https://jamanetwork.com/journals/jama/fullarticle/2810696

AC in ICH - ENRICH AF

Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547

-  Lancet Neurology Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0

-  ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1

II.  TAVI vs SAVR

Low-Risk TAVR Studies: Divergent Long-Term Results 

https://www.medscape.com/viewarticle/997784

-  Partner 3 Main Results

-  Partner 3 – Five Year

-  Original EVOLUT -LR https://www.nejm.org/doi/10.1056/NEJMoa1816885

-  EVOLUT 3-year https://doi.org/10.1016/j.jacc.2023.02.017

-  EVOLUT -LR 4-year https://doi.org/10.1016/j.jacc.2023.09.813

III. Myocardial Viability

Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2

https://www.medscape.com/viewarticle/989101

-  Revived BCIS – Original paper  https://www.nejm.org/doi/10.1056/NEJMoa2206606

-  JAMA Cardiology Viability paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2810727

-  STICH Viability Paper - https://www.nejm.org/doi/full/10.1056/NEJMoa1100358

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net